繁體版 / 簡體版
 
R&D PORTFOLIO
/ MB-110

MB-110

Indication
Hepatitis C
Product Advantages
superior inhibition capacity against prevalent HCV genotypes in Asia (1b, 2a and 3a)
Status
Obtained the investigational new drug (IND) approval from FDA for human clinical trial
Mechanism
Small molecule, highly active and selective inhibitor of NS5A protein of hepatitis C virus (HCV)
Potential Market
According to the statistics of the World Health Organization, about 700,000 people die of liver diseases related to hepatitis C every year. By 2015, the global market has reached 24 billion U.S. dollars. According to the IMS data, the global anti-hepatitis C drug will reach 36 billion U.S. dollars by 2020

Pre-clinical results

MB-110(NSFAI003, DBPR110) has better bioavailability and longer half-life
Good biological stability
 

Mechanism


陕西快乐十分中奖技巧 黑龙江p62几点开奖 3d千禧试机号 (★^O^★)MG大航海时代巨额大奖视频 (^ω^)MG湛蓝深海试玩 广东36选7开奖结果 亿客隆平台 (*^▽^*)MG丛林快讯_最新版 (-^O^-)MG冒险丛林游戏说明 快3计算公式绝 几个可靠真实的网赚 (*^▽^*)MG龙之王国巨额大奖视频 好运彩3玩法 贵州快3形态走势图今天 (^ω^)MG青龙出海援彩金 福利彩票35选7走势图 海南41开奖结果查询